Journal Watch · Frontiers in Immunology · 2026
Neurotoxicity of immune checkpoint inhibitors: a retrospective pharmacovigilance study using FAERS database.
In clinical practice, the early recognition and management of ICI-related n-irAEs are critical.
TL;DR
In clinical practice, the early recognition and management of ICI-related n-irAEs are critical.
Key findings
- The median time to the onset of adverse events was 30 days.
- Serious reports accounted for a high proportion of the patients (91.23%).<h4>Conclusion</h4>Pharmacovigilance analysis indicated that neurological immune-related adverse events associated with ICIs mainly involved central nervous system inflammation and neuromuscular junction dysfunction.
- Different ICI immunotherapies are associated with distinct neurological disease characteristics, and combination therapies may influence the reporting patterns of neurotoxicity.
- In clinical practice, the early recognition and management of ICI-related n-irAEs are critical.
Numbers at a glance (from the abstract)
Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.
What they did
Classification and statistics were conducted using the system organ class (SOC), high-level group term (HLGT), and preferred term (PT) from the Medical Dictionary for Regulatory Activities (MedDRA) terminology set (version 28.0).<h4>Results</h4>The entire FAERS database included 56,321,150 adverse event records, of which 26,629 records were identified as being related to neurological immune-related adverse events (n-irAEs) following ICI therapy. The main adverse events include encephalitis, encephalopathy, myasthenia gravis, paraneoplastic syndromes, and peripheral neuropathy. Among these reports, males (53.51%) outnumbered females (37.82%), and the median patient age was 67 years. The number of reports in 2024 was slightly higher than that in other years, but the difference was not significant. Physicians were the primary reporters (43.23%) and the United States had the highest number of reports (35.78%).
Full abstract (original)
Background: <h4>Background</h4>Immune checkpoint inhibitors (ICIs), an antitumor therapeutic strategy, have shown great potential for cancer treatment. With the widespread use of ICIs, immune-related adverse events (irAEs) have increased gradually. Neurotoxicity, as an irAE, has a low incidence rate, but high disability and mortality rates, warranting clinical attention.<h4>Material and methods</h4>This study aimed to quantify the association between neurological adverse events and ICI treatment and describe the characteristics of ICI-related neurological complications in real-world practice. Data were sourced from the FDA Adverse Event Reporting System (FAERS) database from the first quarter of 2004 to the first quarter of 2025. Data mining was performed using the reporting odds ratio (ROR) method.
What they did: Classification and statistics were conducted using the system organ class (SOC), high-level group term (HLGT), and preferred term (PT) from the Medical Dictionary for Regulatory Activities (MedDRA) terminology set (version 28.0).<h4>Results</h4>The entire FAERS database included 56,321,150 adverse event records, of which 26,629 records were identified as being related to neurological immune-related adverse events (n-irAEs) following ICI therapy. The main adverse events include encephalitis, encephalopathy, myasthenia gravis, paraneoplastic syndromes, and peripheral neuropathy. Among these reports, males (53.51%) outnumbered females (37.82%), and the median patient age was 67 years. The number of reports in 2024 was slightly higher than that in other years, but the difference was not significant. Physicians were the primary reporters (43.23%) and the United States had the highest number of reports (35.78%).
Results & conclusions: The median time to the onset of adverse events was 30 days. Serious reports accounted for a high proportion of the patients (91.23%).<h4>Conclusion</h4>Pharmacovigilance analysis indicated that neurological immune-related adverse events associated with ICIs mainly involved central nervous system inflammation and neuromuscular junction dysfunction. Different ICI immunotherapies are associated with distinct neurological disease characteristics, and combination therapies may influence the reporting patterns of neurotoxicity. In clinical practice, the early recognition and management of ICI-related n-irAEs are critical.
Abstract © the authors / Frontiers in Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.3389/fimmu.2026.1769013 · PubMed 41972167.
Why it matters for pharma & biotech
- Directly relevant to teams in targeted oncology / immuno-oncology, small-molecule drug discovery — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
- Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Modalities & themes detected: targeted oncology / immuno-oncology · small-molecule drug discovery
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
Frequently asked questions
What did this Frontiers in Immunology study find?
In clinical practice, the early recognition and management of ICI-related n-irAEs are critical.
What type of study is this?
It is a cohort / observational clinical study, published in Frontiers in Immunology in 2026. Classification and statistics were conducted using the system organ class (SOC), high-level group term (HLGT), and preferred term (PT) from the Medical Dictionary for Regulatory Activities (MedDRA) terminology set (version 28.0).<h4>Results</h4>The entire FAERS database included 56,321,150 adverse event records, of which 26,629 records were identified as being related to neurological immune-related adverse events (n-irAEs) following ICI therapy.
Where can I read the original paper?
The original is at the publisher via DOI 10.3389/fimmu.2026.1769013. PubMed ID: 41972167. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/neurotoxicity-of-immune-checkpoint-inhibitors-a-retrospective-pharmacovi-769013/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides